Clinical Trials Logo

Down Syndrome clinical trials

View clinical trials related to Down Syndrome.

Filter by:

NCT ID: NCT01545674 Terminated - Aneuploidy Clinical Trials

Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial

PreNATUS
Start date: January 2012
Phase:
Study type: Observational

This prospective blinded study will assess the diagnostic capability of an informatics enhanced SNP based technology (Parental Support) to identify pregnant women who are carrying a fetus with an aneuploidy from fee floating DNA in the maternal blood.

NCT ID: NCT00754052 Terminated - Down Syndrome Clinical Trials

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of the cognitive dysfunction shown by children with Down syndrome, aged 11 to 17.

NCT ID: NCT00754013 Terminated - Down Syndrome Clinical Trials

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.

NCT ID: NCT00675025 Terminated - Down Syndrome Clinical Trials

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

Start date: April 4, 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety of donepezil hydrochloride (Aricept) in children with Down syndrome who have finished the preceding 10-week, double-blind study of donepezil hydrochloride. Medical tests for drug safety will be conducted at each clinic visit.

NCT ID: NCT00643955 Terminated - Down Syndrome Clinical Trials

Neuromuscular Characteristics of Individuals With Down Syndrome (DS)

Start date: March 2008
Phase:
Study type: Observational

Evaluation of muscle strength and central activation of muscle in individuals with Down Syndrome

NCT ID: NCT00327951 Terminated - Clinical trials for Congenital Disorders

Infant Weight Gain With Trisomy 21 and CAVC

Start date: January 2001
Phase: N/A
Study type: Observational

Failure to thrive and difficulty gaining weight is a sign of uncompensated congestive heart failure (CHF). Infants with Trisomy 21 and complete atrioventricular canal defects (CAVC) frequently develop uncompensated CHF and weight gain failure pre-operatively. A weight of 5 kg has been suggested as optimal for timing of CAVC repair. A delay in surgical repair often occurs if weight gain stalls and reaches a plateau prior to reaching 5 kg. A retrospective review performed by Kogon, et al, of children undergoing surgery for VSD at CHOA at Egleston recently reported that age and weight at surgery may not, however, be associated with adverse surgical outcome. The purpose of this study is to determine the optimal timing for surgical correction of CAVC in Trisomy 21 infants based on reaching a plateau of failed weight gain despite maximal anti-congestive and nutritional therapy.

NCT ID: NCT00001178 Terminated - Dementia Clinical Trials

Brain Study of Patients With Frontal Lobe Dementia and Parkinsonian Disorders

Start date: January 19, 1981
Phase:
Study type: Observational

The Cognitive Neuroscience Section of the National Institute of Neurological Disorders and Stroke proposes to continue its cross-sectional and longitudinal studies of cerebral metabolism in frontal lobe dementias and atypical basal ganglia disorders. These studies include repeated assessments of neuropsychological and brain anatomical and metabolic function in subjects with these important and possibly related brain disorders.